Global Brain Tumor Diagnosis and Treatments Market: Snapshot
The demand in the global market for brain tumor diagnosis and treatments is anticipated to increase at a potent CAGR of 8.5% during the forecast period of 2017 to 2025. The prosperity of this market is primarily a reflection of innovations in drug delivery to brain cancer cells, increasing prevalence of brain cancer, rising aging population, and growing incidences of cancer via chemical exposure. On the other hand, exponentially high cost of diagnostic as well as treatment is the most prominent hindrance over this market. The global for brain tumor diagnosis and treatments market was worth US$406.0 mn in 2016, and is estimated to reach a valuation of US$840.7 mn by the end of the forecast period, which is 2025.
CT-Scan Remains High-Demand Diagnosis Segment
Based on product-type, the global brain tumor diagnosis and treatments market has been segmented into primary brain tumor and secondary brain tumor. The primary brain tumor segment, which accounted for 74.7% of the overall demand in 2016, has been sub-segmented into common tumors such as meningioma, astrocytomas, gliomas, and pituitary tumors. Along all sub-segments, meningioma continues to be most prevalent across the world, including Asia Pacific and Europe. It has been observed that in these two regions, CNS and brain tumors are the third most common cancer among young adults and juveniles, causing most of the cancer-related deaths in this age group. The report projects the segment of primary brain tumor to witness an incrementing demand at CAGR of 8.7% during the forecast period from 2017 to 2025.
On the basis of diagnosis type, the global brain tumor diagnosis and treatments market has been bifurcated into CT-Scan, MRI, Molecular Testing, PET-CT Scan, and EEG, with the former accounting for more than 35% share of global market in 2016. It has been noted that CT-Scan remain the most preferred choice of brain cancer diagnosis, owing to their ability to effectively differentiate between bone masses and elaborate soft tissues, besides offering the option to click 3D images in a series at multiple angle. In addition to that, upcoming technological advancements in innovative mobile CT-Scan devices are also expected to aid to the growth of the CT-Scan diagnosis segment during the forecast period. Treatment-wise, surgery category has remained the most preferable primary treatment for brain tumor. It has identified as the first and the only treatment for most type of the brain tumors. That being said, radiation therapy is projected for a strong growth rate during forecast period of 2017 to 2025, a result of growing awareness regarding noninvasive novel treatment due to technological advancements.
Europe Projected for the Best Growth Rate
In 2016, North America accounted for the most prominent share of the demand for brain tumor diagnosis and treatments. The U.S. dominated the brain tumor diagnosis and treatments market in North America, serving about 89.3% share in of North America market in 2016. This dominance is essentially due to the factors such as large number of people diagnosed with brain tumor, extensive research and development activities, technological advancements, and increasing healthcare awareness about the treatment and management of brain tumor are driving market growth. On the other hand, Europe is projected for the best CAGR among all regions during the forecast period, gaining substantial demand from the countries of Germany and The U.K. Rising prevalence of brain tumors disease, escalating percentage of geriatrics among the European population, and government’s initiative regarding growing awareness of advanced technologies are some of the key factors driving the brain tumor diagnosis and treatments market in Europe.
Pfizer, Inc., Toshiba Medical Systems, GE Healthcare, AstraZeneca, Merck & Co., Inc., Siemens Healthineers, Carestream Health, Hitachi Medical Corporation, Philips Healthcare, and Shimadzu Corporation are some of the key companies currently operating in the global brain tumor diagnosis and treatments market.
Global Brain Tumor Diagnosis and Treatments Market: Overview
This report on brain tumor diagnosis and treatments market studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, providing services of brain tumor diagnosis and treatments as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. This section also provides the overall information and data analysis of the global brain tumor diagnosis and treatments market with respect to the leading market segments based on major products type segment, diagnosis type, treatment type and geographies.
Global Brain Tumor Diagnosis and Treatments Market: Segmentation
Based on the product type, the brain tumor diagnosis and treatments market has been segmented into: primary brain tumors (meningioma, gliomas, astrocytomas, pituitary tumors and others) and secondary brain tumors. Each of the market segments have been extensively analyzed based on the market related factors such as increasing rate of brain tumors incidences worldwide, technological advancement, and growing number of use of brain tumor diagnosis and treatments in various geographies. Moreover, historical year-on-year growth have been taken into consideration while estimating the market size. The market size and forecast in terms of US$ million for each segment has been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.
Global Brain Tumor Diagnosis and Treatments Market: Key Research Aspects
The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the brain tumor diagnosis and treatments market and could influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global Brain Tumor Diagnosis and Treatments market.
Geographically, brain tumor diagnosis and treatments market has been segmented into five major regions: North America, Europe, Asia, Latin America, and Middle East & Africa. The market size and forecast for each of these regions has been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The report also provides with market size and forecast for major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market growth and future opportunities has been provided in the market overview section. This section of the report also provides with market attractiveness analysis, Porter’s five forces analysis, value chain analysis, and heat map analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global brain tumor diagnosis and treatments market.
Global Brain Tumor Diagnosis and Treatments Market: Competitive Landscape
The key findings section included in the report would assist existing market players in expanding their market shares, and new companies in establishing their presence in the global brain tumor diagnosis and treatments market.
The report also profiles key players operating in the brain tumor diagnosis and treatments market which are AstraZeneca, Carestream Health, GE Healthcare, Hitachi Medical Corporation, Merck & Co., Inc., Philips Healthcare, Pfizer, Inc., Shimadzu Corporation, Siemens Healthineers, Toshiba Medical Systems Corporation and other prominent players.
The global brain tumor diagnosis and treatments market is segmented as follows:
Brain Tumor Diagnosis and Treatments Market, by Product Type
- Primary Brain Tumor
- Pituitary Tumors
- Secondary Brain Tumor
Brain Tumor Diagnosis and Treatments Market, by Diagnosis Type
- CT Scan
- PET-CT Scan
- Molecular Testing
Brain Tumor Diagnosis and Treatments Market, by Treatment Type
- Radiation Therapy
- Targeted Therapy
Brain Tumor Diagnosis and Treatments Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa